Compared with placebo , patients receiving omega-3 PUFA had lower Lp-PLA2 mass by 9.42 % , activity by 9.2 ( p = 0.041 for both ) and oxy-LDL by 12.3 % ( p = 0.10 ) after one month , but not at 3-5 days .